News

Innovation alliance unveils new name and strategic plan for Western Virginia

A strategic alliance has a new name — Verge — and a new vision of acting as the front door for an innovation economy that stretches from Lynchburg to the New River Valley.

Formed last year, the alliance is a joint mission of the Valleys Innovation Council, the Roanoke-Blacksburg Technology Council and the Regional Accelerator and Mentoring Program, known as RAMP.

At a virtual news conference Monday, organizers said the unified strength of the three organizations will help solidify connections and better leverage emerging opportunities for the region’s technologists, innovators and entrepreneurs.

Verge will focus on the technology and life sciences innovation ecosystem in the GO Virginia Region 2, a sprawling span of the state that includes the Roanoke and New River valleys, the Alleghany Highlands and the Lynchburg region.

“What is happening in technology in this part of Virginia is really exciting,” CEO Greg Feldmann said in a statement.

“By aligning the efforts of three distinct but synergistic entities, we will all more effectively develop external resourcing, more efficiently implement new programs ensuring each reaches the right audiences at the right moments and in the right contexts to provide maximum value.

“It’s all about comprehensively supporting the many people and organizations who are investing in and shaping the economic future of our region.”

While collaborating in the newly defined joint mission, the three organizations will continue their day-to-day operations under the same leadership.

Recent News

04/01/2025

ReAlta Life Sciences Announces Appointment of Distinguished Immunologist, Laurie Glimcher, M.D., to Board of Directors

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases,  announced the appointment of Laurie Glimcher, M.D., to its Board of Directors, effective immediately. Dr. Glimcher is a distinguished immunologist widely renowned for her work in cancer

03/31/2025

Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients

Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the preliminary results of improvements to key enzymes for Bonumose’s ingredient production process. Bonumose enzyme breakthroughs include unique combinations converting plant-based starch and

03/26/2025

New survey: U.S. biotechs warn tariffs could impede access to cures, stifle innovation

Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90% of U.S. biotech companies rely on imported components for at least half of their FDA-approved products — making the supply of medicines for US patients and